Merck (MRK), known as MSD outside the U.S. and Canada, announced Friday that the U.S. Food and Drug Administration (FDA) approved supplemental New Drug Applications (sNDAs) for PIFELTRO (in combination with other antiretroviral agents) and DELSTRIGO (as a complete regimen) that expand their indications to include adult patients with HIV-1 infection.
from RTT - Biotech https://ift.tt/2Ax7SBZ
via IFTTT
No comments:
Post a Comment